NeuroFrontiers
Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health.
So if you want to stay up to date on the latest clinical research and news on neurological disorders, then look no further. Because NeuroFrontiers is where neurology specialists and great minds explore the mind itself.
181-195 of 381
Navigating Myasthenia Gravis in Adolescents and Young Adults
NeuroFrontiersNavigating Myasthenia Gravis in Adolescents and Young Adults
Jonathan Strober, MD
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
NeuroFrontiersRozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
Gil I. Wolfe MD, FAAN
Challenges in DMD: Understanding the Height Factor
NeuroFrontiersChallenges in DMD: Understanding the Height Factor
FcRn Inhibitors: A Potential New Targeted Therapy Option
NeuroFrontiersFcRn Inhibitors: A Potential New Targeted Therapy Option
Nicholas J. Silvestri, MD
Henry Kaminski, MD
Unseen Struggles: Impacts of Homelessness on Women with Schizophrenia
NeuroFrontiersUnseen Struggles: Impacts of Homelessness on Women with Schizophrenia
- advertisement
Examining Schizophrenia Risk: The Influence of B12 Levels in Early Pregnancy
NeuroFrontiersExamining Schizophrenia Risk: The Influence of B12 Levels in Early Pregnancy
NKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
NeuroFrontiersNKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
Beyond Amyloid and Tau: A Multimarker Approach to Alzheimer's Detection
NeuroFrontiersBeyond Amyloid and Tau: A Multimarker Approach to Alzheimer's Detection
Thomas Karikari, PhD
Preventing Alzheimer’s Disease Through Lifestyle Interventions
NeuroFrontiersPreventing Alzheimer’s Disease Through Lifestyle Interventions
Michele Longo, MD
Amyloid-Targeted Therapies: A New Era in Alzheimer’s Disease Treatment
NeuroFrontiersAmyloid-Targeted Therapies: A New Era in Alzheimer’s Disease Treatment
Michele Longo, MD
Transforming Schizophrenia Treatment: Advances in Medication and Therapy
NeuroFrontiersTransforming Schizophrenia Treatment: Advances in Medication and Therapy
Robert Walker, PharmD
Deanna L. Kelly, PharmD, BCPP
- advertisement
Advancing Schizophrenia Care: Challenges and Promising New Therapies
NeuroFrontiersAdvancing Schizophrenia Care: Challenges and Promising New Therapies
Charles Turck, PharmD, BCPS, BCCCP
Andrew J. Cutler, MD
Debunking Misconceptions Regarding the Revised Alzheimer’s Diagnostic Criteria
NeuroFrontiersDebunking Misconceptions Regarding the Revised Alzheimer’s Diagnostic Criteria
Clifford Jack Jr., MD
Reviewing the Revised Alzheimer’s Diagnostic Criteria: The Role of Biomarkers
NeuroFrontiersReviewing the Revised Alzheimer’s Diagnostic Criteria: The Role of Biomarkers
Clifford Jack Jr., MD
